US 12,281,171 B2
Periostin antibodies and methods of using the same
Karen Abbott, Little Rock, AR (US); and Nathalie Scholler, Playa Del Rey, CA (US)
Assigned to Bio Ventures, LLC, Little Rock, AR (US); and SRI International, Menlo Park, CA (US)
Appl. No. 16/982,476
Filed by BioVentures, LLC, Little Rock, AR (US); and SRI International, Menlo Park, CA (US)
PCT Filed Mar. 19, 2019, PCT No. PCT/US2019/023020
§ 371(c)(1), (2) Date Sep. 18, 2020,
PCT Pub. No. WO2019/183131, PCT Pub. Date Sep. 26, 2019.
Claims priority of provisional application 62/727,915, filed on Sep. 6, 2018.
Claims priority of provisional application 62/644,681, filed on Mar. 19, 2018.
Prior Publication US 2021/0017288 A1, Jan. 21, 2021
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 49/0058 (2013.01); A61K 49/16 (2013.01); C07K 16/3023 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01)] 13 Claims
 
1. An antigen-binding reagent comprising a heavy chain variable region comprising SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 6, wherein the antigen-binding reagent specifically binds to a bisecting N-glycan epitope of the human Periostin glycoprotein.